Weight loss relapse associated with exposure to perfluoroalkylate substances
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Weight loss relapse associated with exposure to perfluoroalkylate substances. / Grandjean, Philippe; Meddis, Alessandra; Nielsen, Flemming; Sjödin, Anders; Hjorth, Mads Fiil; Astrup, Arne; Budtz-Jørgensen, Esben.
In: Obesity, Vol. 31, No. 6, 2023, p. 1686-1696.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Weight loss relapse associated with exposure to perfluoroalkylate substances
AU - Grandjean, Philippe
AU - Meddis, Alessandra
AU - Nielsen, Flemming
AU - Sjödin, Anders
AU - Hjorth, Mads Fiil
AU - Astrup, Arne
AU - Budtz-Jørgensen, Esben
N1 - Publisher Copyright: © 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
PY - 2023
Y1 - 2023
N2 - Objective: The purpose of this study was to test the hypothesis that perfluorinated alkylate substance (PFAS) exposures are associated with body weight increases in a dietary intervention study. Methods: In the DioGenes trial, adults with obesity first lost at least 8% of their body weight and then completed at least 26 weeks on a specific diet. Concentrations of five major PFASs were assessed in plasma samples from study baseline. Results: In 381 participants with complete data, plasma concentrations averaged 2.9 ng/mL and 1.0 ng/mL for perfluorooctanoic acid (PFOA) and perfluorohexanesulfonic acid (PFHxS), respectively. A doubling in plasma PFOA was associated with an increase in weight at 26 weeks by 1.50 kg (95% CI: 0.88–2.11), with an increase of 0.91 kg (95% CI: 0.54–1.27) for PFHxS, independent of diet groups and sex. Associations for other PFASs were in the same direction and significant, although not after adjustment for PFOA and PFHxS. Weight changes associated with elevated PFAS exposures were similar to or larger than average changes ascribed to the different diet groups. Conclusions: Elevated plasma concentrations of PFOA and PFHxS were associated with increased weight gain that exceeded those related to the diets. Obesogenic PFASs may cause weight gain and thus contribute to the obesity pandemic.
AB - Objective: The purpose of this study was to test the hypothesis that perfluorinated alkylate substance (PFAS) exposures are associated with body weight increases in a dietary intervention study. Methods: In the DioGenes trial, adults with obesity first lost at least 8% of their body weight and then completed at least 26 weeks on a specific diet. Concentrations of five major PFASs were assessed in plasma samples from study baseline. Results: In 381 participants with complete data, plasma concentrations averaged 2.9 ng/mL and 1.0 ng/mL for perfluorooctanoic acid (PFOA) and perfluorohexanesulfonic acid (PFHxS), respectively. A doubling in plasma PFOA was associated with an increase in weight at 26 weeks by 1.50 kg (95% CI: 0.88–2.11), with an increase of 0.91 kg (95% CI: 0.54–1.27) for PFHxS, independent of diet groups and sex. Associations for other PFASs were in the same direction and significant, although not after adjustment for PFOA and PFHxS. Weight changes associated with elevated PFAS exposures were similar to or larger than average changes ascribed to the different diet groups. Conclusions: Elevated plasma concentrations of PFOA and PFHxS were associated with increased weight gain that exceeded those related to the diets. Obesogenic PFASs may cause weight gain and thus contribute to the obesity pandemic.
KW - Faculty of Science
KW - PFAS
KW - Body weight
KW - Weight gain
KW - Dietary intervention
U2 - 10.1002/oby.23755
DO - 10.1002/oby.23755
M3 - Journal article
C2 - 37069729
AN - SCOPUS:85153188019
VL - 31
SP - 1686
EP - 1696
JO - Obesity
JF - Obesity
SN - 1930-7381
IS - 6
ER -
ID: 346140401